Fenwick Represents Gritstone Oncology in IP Due Diligence of $97.5 Million Series B Financing

Fenwick & West represented Gritstone Oncology, a next-generation personalized cancer immunotherapy company, in the intellectual property due diligence aspect of its $97.5 million Series B financing. Lilly Asia Ventures led the round, with participation from GV (formerly Google Ventures), Trinitas Capital, Alexandria Venture Investments, Versant Ventures, The Column Group, Clarus Funds and Frazier Healthcare Partners.

The funding will be used to support the ongoing construction and completion of Gritstone’s 43,000 square foot industrialized manufacturing facility, which is being built in compliance with current Good Manufacturing Practices (cGMP) and will be the center of Gritstone’s manufacturing program for personalized cancer therapeutics.

The Fenwick team was led by intellectual property attorneys Michael Shuster, Kevin Kabler, Andrew Whitehead, with the support of patent agents Zachary Newman and Claire Baek.